Ipratropium bromide/Salbutamol Neutec 0.5/2.5 mg per 2.5 ml nebuliser solution Irlanda - inglese - HPRA (Health Products Regulatory Authority)

ipratropium bromide/salbutamol neutec 0.5/2.5 mg per 2.5 ml nebuliser solution

neutec inhaler ireland limited - ipratropium bromide monohydrate; salbutamol sulfate - nebuliser solution - salbutamol and ipratropium bromide

ULORIC- febuxostat tablet Stati Uniti - inglese - NLM (National Library of Medicine)

uloric- febuxostat tablet

rebel distributors corp - febuxostat (unii: 101v0r1n2e) (febuxostat - unii:101v0r1n2e) - febuxostat 80 mg - uloric® is a xanthine oxidase (xo) inhibitor indicated for the chronic management of hyperuricemia in patients with gout. uloric is not recommended for the treatment of asymptomatic hyperuricemia. uloric is contraindicated in patients being treated with azathioprine, mercaptopurine, or theophylline [see drug interactions (7)] . pregnancy category c : there are no adequate and well-controlled studies in pregnant women. uloric should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. febuxostat was not teratogenic in rats and rabbits at oral doses up to 48 mg per kg (40 and 51 times the human plasma exposure at 80 mg per day for equal body surface area, respectively) during organogenesis. however, increased neonatal mortality and a reduction in the neonatal body weight gain were observed when pregnant rats were treated with oral doses up to 48 mg per kg (40 times the human plasma exposure at 80 mg per day) during organogenesis and through lactation period. febuxos